Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | FDFT1 | P37268 | 3/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GNA15 | P30679 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501980 | 0.94 | GAA (0.69) | GAABCHETSHRHSD17B10FFAR1 | |
| SCHEMBL6499688 | 0.87 | CYP1A2 (0.56) | GAABCHETSHRHSD17B10FFAR1 | |
| SCHEMBL6508701 | 0.85 | KDM4E (0.50) | BCHETSHRHSD17B10MEN1KMT2A | |
| SCHEMBL6508928 | 0.84 | GAA (0.62) | GAABCHEHPGDKDM4ELMNA | |
| SCHEMBL6503729 | 0.83 | EPHX2 (0.58) | BCHETSHRHSD17B10MEN1KMT2A | |
| SCHEMBL6505391 | 0.83 | TSHR (0.52) | BCHETSHRHSD17B10MEN1KMT2A | |
| SCHEMBL6507435 | 0.83 | RAB9A (0.49) | BCHETSHRHSD17B10MEN1KMT2A | |
| SCHEMBL6504830 | 0.82 | BCHE (0.54) | GAABCHETSHRHSD17B10FFAR1 | |
| SCHEMBL6498720 | 0.81 | BCHE (0.59) | BCHETSHRHSD17B10KMT2ALMNA | |
| SCHEMBL6506029 | 0.81 | LMNA (0.55) | GAABCHETSHRHSD17B10FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | GAA 2177/4885BCHE 945/4885TSHR 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.